Icecure Medical Ltd. key statistics and ratios
In fiscal 2025, Icecure Medical Ltd. had return on equity of -188.8%, an operating margin of -446.7%, debt equal to 0.1% of equity and a current ratio of 2.61. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross margin | 32.2% | 63.2% | 53.0% | 46.8% | 40.3% | 44.1% | 36.3% |
| Operating margin | −294.0% | −107.1% | −235.0% | −542.6% | −482.4% | −476.9% | −446.7% |
| Net margin | −279.7% | −96.4% | −239.1% | −550.3% | −453.8% | −465.5% | −445.6% |
| Free-cash-flow margin | −128.6% | −101.2% | −317.5% | −492.2% | −403.5% | −383.9% | −432.4% |
| Return on equity | −138.3% | −83.5% | −60.7% | −64.8% | −78.0% | −160.7% | −188.8% |
| Return on assets | — | −36.4% | −46.5% | −54.4% | −62.9% | −105.7% | −113.8% |
| Asset turnover | — | 0.38 | 0.19 | 0.10 | 0.14 | 0.23 | 0.26 |
| Current ratio | — | 2.58 | 7.54 | 6.49 | 3.66 | 1.95 | 2.61 |
| Debt to equity | 0.0% | 13.4% | 2.3% | — | 0.0% | 2.3% | 0.1% |
| R&D as % of revenue | 184.4% | 98.5% | 142.0% | 295.7% | 256.2% | 215.6% | 220.0% |
| SG&A as % of revenue | — | 3.1% | 4.3% | 23.8% | — | — | — |
| Capital spending as % of revenue | 6.3% | 5.8% | 12.9% | 28.9% | 14.9% | 2.2% | 1.1% |
Financial health
- Short-term assets cover short-term liabilities $13m of assets due within a year against $5m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt $9m of cash against $13,000 of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$15m of operating cash flow against $13,000 of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Compare with peers
- Cerenome, Inc. statistics
- Intelligent BIO Solutions Inc. statistics
- Biomerica Inc statistics
- Volitionrx LTD statistics
- Charming Medical Ltd statistics
Head to head: CNSY vs ICCMICCM vs INBSBMRA vs ICCMICCM vs VNRX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies